Skip to content

Diagnosis and phenotyping

TL;DR — HHD diagnosis requires two linked demonstrations: credible cumulative pressure exposure and a cardiac phenotype plausibly attributable to it. Office BP alone misclassifies white-coat, masked and nocturnal hypertension; ambulatory or home measurement clarifies exposure (Huang 2021, PMID 33390042). ECG is specific but insensitive for anatomical LVH—30.7% sensitivity and 84.4% specificity in a 13,960-person clinical cohort—so a negative tracing does not exclude remodeling (Bressman 2020, PMID 32194027). Echocardiography is the practical first phenotyping tool; CMR is the reference for mass/volumes and adds fibrosis and differential diagnosis. CMR separates HHD from HCM at group level, not by one portable cutoff (Zhao 2024, PMID 39156132). No universal test confirms hypertension as the cause; the diagnosis remains probabilistic and exclusion-aware.

1. Diagnostic architecture

Question Minimum evidence Escalation when uncertain
Is pressure exposure real? Repeated standardized office BP ABPM, structured home BP, record trajectory
Is cardiac injury present? ECG plus clinical assessment Echo with geometry, function and atrial assessment
What tissue/etiology? Echo pattern and history CMR with LGE/T1/ECV; targeted testing
Is HF present? Symptoms/signs plus objective dysfunction/congestion Exercise echo or invasive exercise hemodynamics
Is hypertension causal? Temporal exposure + compatible phenotype Exclude valve, ischemic, genetic, infiltrative and toxic causes
Is the finding prognostic/actionable? Validated cohort/trial evidence Avoid acting on unvalidated thresholds

The term HHD should follow this architecture rather than appear automatically whenever hypertension and any heart disease coexist (Nwabuo 2020, PMID 32016791; Nemtsova 2023, PMID 37048689).

2. Confirming pressure exposure

Standardized office measurement

Office BP is sensitive to device validation, cuff size, rest, positioning, repeated readings, observer effects and recent activity. Guidelines differ on diagnostic labels and targets, so reports should state the protocol and governing framework (Jones 2025, PMID 40815242; McEvoy 2024, PMID 39210715).

Ambulatory measurement

ABPM supplies 24-hour, daytime and nighttime levels and distinguishes sustained, white-coat and masked phenotypes. Longitudinal evidence links 24-hour and nighttime BP more closely to cardiovascular outcomes than office BP, and participant-level evidence shows out-of-office measurement improves risk stratification in apparently normal or borderline clinic categories (Huang 2021, PMID 33390042; Asayama 2014, PMID 25139777).

In 11,135 adults followed median 13.8 years, each 20-mm Hg higher 24-hour systolic BP was associated with cardiovascular-event HR 1.45 (95% CI 1.37–1.54); nighttime systolic BP carried HR 1.36 (1.30–1.43) (Yang 2019, PMID 31386134).

Phenotype Office BP Out-of-office BP HHD interpretation
Sustained normotension Normal Normal Hypertensive attribution weak unless historical treatment/exposure
White-coat hypertension High Normal Avoid over-attribution; longitudinal risk still context-dependent
Masked hypertension Normal High Cardiac injury may be the clue to missed exposure
Sustained hypertension High High Stronger exposure evidence
Nocturnal hypertension Variable Night high Particularly relevant to CKD, OSA and LVH
Treated controlled Target range Target range Historical cumulative load still matters

An individual-participant meta-analysis of 14,230 people linked more 24-hour time within the 2024 ESC ambulatory target range to lower mortality (standardized HR 0.57) and cardiovascular endpoints (HR 0.30), but this observational association is not proof of a treatment target for HHD (Zhang 2025, PMID 40249369).

Home measurement

Home BP is complementary rather than interchangeable in every circumstance: it lacks sleep measurements but enables repeated real-world sampling. Individual-patient meta-analysis found self-monitoring reduced clinic systolic BP by 3.2 mm Hg (95% CI 1.6–4.9), with no effect from monitoring alone and larger effects with intensive co-intervention (Tucker 2017, PMID 28926573).

The 622-person HOME BP trial found one-year mean BP 138.4/80.2 versus 141.8/79.8 mm Hg with digitally supported self-management versus usual care (McManus 2021, PMID 33468518).

3. ECG: electrical phenotype, not anatomical gatekeeper

ECG can identify voltage, repolarization strain, conduction disease, prior infarction and rhythm. It is cheap and prognostic, but anatomical sensitivity is low.

Evidence Finding Meaning
21-study systematic review; 5,608 hypertensive patients Median negative likelihood ratios 0.85–0.91 across criteria Negative ECG barely lowers LVH probability (Pewsner 2007, PMID 17726091)
13,960-patient clinical cohort Sensitivity 30.7%; specificity 84.4% ECG misses most echo-LVH (Bressman 2020, PMID 32194027)
1,789 older Chinese adults Cornell product had best agreement/AUC among three tested criteria Performance depends on population and echo definition (Zhang 2019, PMID 30880935)

ECG-LVH and imaging-LVH are related but biologically nonidentical; both can carry prognosis (Alfakih 2006, PMID 16794466).

4. Echocardiography: first-line phenotype

Domain Core measures Interpretation trap
LV size/mass Linear or 2D/3D dimensions, indexed mass Formula and indexation dependence
Geometry RWT plus mass Load and threshold dependence
Systolic function EF, GLS Preserved EF can hide impaired longitudinal function
Diastolic function e′, E/e′, LA volume, TR velocity Age, rhythm and loading conditions
Atrial phenotype LA volume and strain AF/mitral disease confounding
Valve/aorta Stenosis, regurgitation, root/ascending aorta Competing pressure or volume load
Right heart RV function and pulmonary pressure Lung disease and volume status

Echo is practical for serial assessment but has observer, acoustic-window and geometric-assumption variability. A structured report should preserve raw measures, not only a binary “LVH present” label (Ismail 2023, PMID 37176563; Tadic 2021, PMID 32170529).

5. CMR: reference anatomy plus tissue

CMR offers reproducible LV mass and volume without geometric assumptions, tissue characterization and ischemia/aortic evaluation. Access, cost, scan tolerance, rhythm, gadolinium constraints and platform-specific mapping values limit universality (Mavrogeni 2017, PMID 28535761; Tadic 2021, PMID 32170529).

CMR signal Potential HHD information Non-specificity
Cine mass/geometry Quantitative remodeling Loading and body-size indexation
LGE Focal replacement fibrosis/pattern Scar from ischemic or other cardiomyopathy
Native T1 Diffuse tissue signal Platform, edema, amyloid and other disease
ECV Extracellular expansion Hematocrit and sequence dependence
Feature-tracking strain Mechanical dysfunction Software and load dependence
Perfusion/flow reserve Microvascular ischemia CAD and technical factors

6. HHD versus HCM, amyloid and athletic remodeling

A 26-study meta-analysis (1,349 HHD; 1,581 HCM) found HHD lower than HCM in native T1 (Hedges g −0.469), ECV (−0.417), LV-mass index (−0.437) and maximal wall thickness (−2.076), with higher end-systolic and end-diastolic volume indices (Zhao 2024, PMID 39156132). These are distributions, not universal patient cutoffs.

In 224 participants, CMR feature-tracking GLS discriminated HHD from HCM with c-statistic 0.639; native T1 achieved 0.718 and LGE volume 0.680 (Neisius 2019, PMID 31433823).

A 314-person multiparametric study reported combined strain and atypical LGE sensitivity 82% and specificity 100% for HHD versus HCM within its sample; the same algorithm requires external validation before clinical portability (Giusca 2021, PMID 34247623).

For the amyloid arm of the differential, an ECG-based deep-learning model was developed at Yale New Haven Health (28,174 ECGs from 11,291 patients, 293 with transthyretin amyloid cardiomyopathy) and temporally validated in 44,123 patients, with AUROC 0.84 (95% CI 0.79–0.89) and, at the prespecified threshold, sensitivity 0.72 and specificity 0.86 against amyloid confirmed by radionuclide imaging or biopsy. The result relevant here is the specificity stress test: restricted to patients with LVH or severe aortic stenosis without amyloid — the mimics that matter for HHD — AUROC was 0.81 (0.75–0.86), and among patients referred for cardiac amyloid radionuclide imaging it was 0.78 (0.73–0.84). External AUROCs across five multinational cohorts ranged 0.78–0.89 (Croon 2026, PMID 42663420).

This is a triage tool for a competing diagnosis, not an HHD test, and its positive predictive value depends on amyloid prevalence in the population screened. Its practical relevance to HHD is that ECG-level triage for ATTR-CM may be deployable where CMR and bone-tracer imaging are not — the same resource asymmetry that constrains HHD phenotyping.

Feature HHD tendency Alternative clue
Hypertrophy pattern Often concentric/moderate Asymmetric/focal HCM; apical variants
LV cavity Often preserved or enlarged Small cavity in some HCM/amyloid phenotypes
LGE Absent or nonspecific patchy Ischemic subendocardial; amyloid diffuse; HCM insertion/patchy
Native T1/ECV Mild–moderate group-level elevation Marked amyloid elevation; disease-specific context
Family history/genetics Usually absent Supports inherited cardiomyopathy
Extracardiac findings Hypertension target-organ pattern Neuropathy, proteinopathy or syndromic clues

7. HFpEF phenotyping under load

For unexplained exertional dyspnea, resting studies may be nondiagnostic. H₂FPEF uses obesity, AF, age, antihypertensive count, E/e′ and pulmonary pressure; odds of invasively confirmed HFpEF doubled per point in derivation/validation (Reddy 2018, PMID 29792299).

HFA-PEFF uses clinical context, comprehensive echo and natriuretic peptides, sending intermediate scores to exercise echo or invasive hemodynamics (Pieske 2019, PMID 31504452).

8. Biomarkers as phenotype enrichers

REMODEL followed 1,054 asymptomatic adults with essential hypertension. Internally selected thresholds of NT-proBNP 152 pg/mL and hs-troponin T 12.7 pg/mL identified higher-risk strata; dual elevation was associated with event HR 17.11 (95% CI 8.12–36.09) (Sharp 2026, PMID 41771092).

These are derivation thresholds, not a standalone HHD diagnosis. Assay calibration, renal function, age, obesity, AF and external validation remain necessary.

9. Differential diagnosis checklist

Alternative Trigger for targeted evaluation
Aortic stenosis Murmur, valve calcification or high Doppler velocity
HCM Disproportionate/asymmetric hypertrophy, family history, unexplained syncope
Cardiac amyloidosis Wall thickening with low voltage, neuropathy, protein clues, characteristic CMR
Fabry disease LVH plus neuropathic pain, renal or skin/ocular clues
Ischemic cardiomyopathy Regional dysfunction/scar or ischemic symptoms
Athlete’s heart Training context, balanced chamber adaptation and deconditioning response
CKD cardiomyopathy Renal dysfunction, anemia, volume/mineral abnormalities
Tachycardia-mediated disease Sustained rapid rhythm and recovery after control

Open questions

  • Can a standardized multimodal algorithm assign HHD causality with external calibration across ancestry, obesity and CKD? (Zhao 2024, PMID 39156132; Nemtsova 2023, PMID 37048689)
  • Does screening asymptomatic hypertension with echo, CMR or biomarkers improve outcomes compared with risk-based treatment alone? (Sharp 2026, PMID 41771092)
  • Which out-of-office BP summary best predicts remodeling regression: mean, nighttime level, variability or time in range? (Yang 2019, PMID 31386134; Zhang 2025, PMID 40249369)
  • What serial imaging interval changes management rather than merely detects change? (Hwang 2025, PMID 40970541; Lertsiripatarajit 2026, PMID 41953289)
  • Does ECG-level artificial-intelligence triage for competing causes of LVH change downstream imaging use and diagnostic yield in hypertensive cohorts? (Croon 2026, PMID 42663420)

References

  1. Huang QF, et al. Ambulatory Blood Pressure Monitoring to Diagnose and Manage Hypertension. Hypertension. 2021;77:254-264. PMID 33390042
  2. Bressman M, et al. Determination of Sensitivity and Specificity of Electrocardiography for Left Ventricular Hypertrophy in a Large, Diverse Patient Population. Am J Med. 2020;133:e495-e500. PMID 32194027
  3. Zhao Q, et al. Cardiac magnetic resonance imaging for discrimination of hypertensive heart disease and hypertrophic cardiomyopathy: a systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1421013. PMID 39156132
  4. Nwabuo CC, et al. Pathophysiology of Hypertensive Heart Disease: Beyond Left Ventricular Hypertrophy. Curr Hypertens Rep. 2020;22:11. PMID 32016791
  5. Nemtsova V, et al. Hypertensive Heart Disease: A Narrative Review Series-Part 1: Pathophysiology and Microstructural Changes. J Clin Med. 2023;12. PMID 37048689
  6. Jones DW, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86:1567-1678. PMID 40815242
  7. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912-4018. PMID 39210715
  8. Yang WY, et al. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes. JAMA. 2019;322:409-420. PMID 31386134
  9. Zhang DY, et al. Ambulatory blood pressure monitoring, European guideline targets, and cardiovascular outcomes: an individual patient data meta-analysis. Eur Heart J. 2025;46:2974-2987. PMID 40249369
  10. Tucker KL, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017;14:e1002389. PMID 28926573
  11. McManus RJ, et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ. 2021;372:m4858. PMID 33468518
  12. Pewsner D, et al. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: systematic review. BMJ. 2007;335:711. PMID 17726091
  13. Zhang W, et al. Consistency of left ventricular hypertrophy diagnosed by electrocardiography and echocardiography: the Northern Shanghai Study. Clin Interv Aging. 2019;14:549-556. PMID 30880935
  14. Alfakih K, et al. The assessment of left ventricular hypertrophy in hypertension. J Hypertens. 2006;24:1223-30. PMID 16794466
  15. Ismail TF, et al. Hypertensive Heart Disease-The Imaging Perspective. J Clin Med. 2023;12. PMID 37176563
  16. Tadic M, et al. Comprehensive assessment of hypertensive heart disease: cardiac magnetic resonance in focus. Heart Fail Rev. 2021;26:1383-1390. PMID 32170529
  17. Mavrogeni S, et al. The emerging role of Cardiovascular Magnetic Resonance in the evaluation of hypertensive heart disease. BMC Cardiovasc Disord. 2017;17:132. PMID 28535761
  18. Neisius U, et al. Cardiovascular magnetic resonance feature tracking strain analysis for discrimination between hypertensive heart disease and hypertrophic cardiomyopathy. PLoS One. 2019;14:e0221061. PMID 31433823
  19. Giusca S, et al. Multi-parametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2021;23:92. PMID 34247623
  20. Reddy YNV, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018;138:861-870. PMID 29792299
  21. Pieske B, et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019;40:3297-3317. PMID 31504452
  22. Sharp A, et al. Role of natriuretic peptides and cardiac troponins in staging hypertensive heart disease: the REMODEL study. Eur J Heart Fail. 2026. PMID 41771092
  23. Hwang IC, et al. Left Ventricular Mass-to-Strain Ratio to Predict Change in Left Ventricular Hypertrophy and Prognosis in Hypertensive Heart Disease. J Am Heart Assoc. 2025;14:e042032. PMID 40970541
  24. Lertsiripatarajit P, et al. Cardiac magnetic resonance assessment of left ventricular phenotypes and prognostic implications in hypertensive heart disease. Clin Hypertens. 2026;32:e14. PMID 41953289
  25. Asayama K, et al. Out-of-office blood pressure improves risk stratification in normotension and prehypertension people. Curr Hypertens Rep. 2014;16:478. PMID 25139777
  26. Croon PM, et al. Electrocardiogram-Based Deep Learning to Prioritize Testing for Transthyretin Amyloid Cardiomyopathy. JAMA. 2026;:e2616785. PMID 42663420